FIBROGEN
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. FibroGe... n's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).
FIBROGEN
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
1993-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.fibrogen.com
Total Employee:
251+
Status:
Active
Contact:
415-978-1200
Total Funding:
188.02 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Domain Not Resolving Sitelinks Search Box IPv6 Google Maps GStatic Google Static Content
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Juan Graham CFO @ FibroGen
CFO
2021-08-01
Michael D. Lowenstein Chief Legal Officer, Corporate Secretary & Compliance Officer @ FibroGen
Chief Legal Officer, Corporate Secretary & Compliance Officer
2002-01-01
Leanne C. Price Vice President, Intellectual Property and Corporate Strategy @ FibroGen
Vice President, Intellectual Property and Corporate Strategy
Ted Tucker Vice President, Human Resources @ FibroGen
Vice President, Human Resources
1997-09-01
Michael Martinelli VP Technical Development @ FibroGen
VP Technical Development
2011-03-01
James W. Polarek Vice President @ FibroGen
Vice President
1995-07-01
Kalevi Kurkijärvi Director @ FibroGen
Director
1995-12-01
Al Lin Vice President, Preclinical Development and Chemical Manufacturing and Control (CMC) @ FibroGen
Vice President, Preclinical Development and Chemical Manufacturing and Control (CMC)
John Hunter Chief Scientific Officer @ FibroGen
Chief Scientific Officer
Danna Liu Senior Manager, Financial Reporting @ FibroGen
Senior Manager, Financial Reporting
2020-02-01
Founder
Stock Details
Investors List
AstraZeneca
AstraZeneca investment in Post-IPO Equity - FibroGen
Apothecary Capital
Apothecary Capital investment in Venture Round - FibroGen
Sigma Capital Group
Sigma Capital Group investment in Venture Round - FibroGen
Astellas Pharma
Astellas Pharma investment in Venture Round - FibroGen
BioFund Management
BioFund Management investment in Venture Round - FibroGen
Corriente Biotechnology Partners
Corriente Biotechnology Partners investment in Venture Round - FibroGen
Adage Capital Management
Adage Capital Management investment in Venture Round - FibroGen
Duquesne Capital Management
Duquesne Capital Management investment in Venture Round - FibroGen
Rosewood Corporation
Rosewood Corporation investment in Venture Round - FibroGen
T. Rowe Price
T. Rowe Price investment in Venture Round - FibroGen
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-16 | FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer |
Official Site Inspections
http://www.fibrogen.com Semrush global rank: 1.82 M Semrush visits lastest month: 12.44 K
- Host name: 172.67.145.36
- IP address: 172.67.145.36
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "FibroGen"
FibroGen - Crunchbase Company Profile & Funding
FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the …See details»
Investor Overview | FibroGen, Inc.
FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call. 03/17/25 5:00 PM EDT We accelerate the delivery of innovative treatments that operate at the cutting edge of cancer …See details»
Executive Team - FibroGen
Under the leadership of Chief Executive Officer Thane Wettig, FibroGen’s executive team includes accomplished leaders with deep and broad experience. Supported by a staff of approximately 300 employees worldwide, we are …See details»
FibroGen, Inc. Management Team | Org Chart - RocketReach
FibroGen, Inc. employs 368 employees. The FibroGen, Inc. management team includes Mike Martinelli (Senior Vice President), Tricia Stewart (Chief People Officer), and Michael …See details»
FibroGen, Inc. - LinkedIn
FibroGen, Inc. | 16,709 followers on LinkedIn. Committed to being a place where our people and science thrive. | We are committed to discovering, developing, and commercializing a pipeline …See details»
FibroGen, Inc. Corporate Presentation
FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its …See details»
Commission file number: 001-36740 FIBROGEN, INC.
FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) …See details»
FibroGen Announces the Sale of FibroGen China to AstraZeneca …
Feb 20, 2025 FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress …See details»
FibroGen - The Org
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia …See details»
FibroGen Reports Fourth Quarter and Full Year 2024 Financial …
5 days ago Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million. Transaction expected to close by mid-2025; ... we will be a leaner …See details»
FibroGen Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 FibroGen has 5 employees at their 1 location and $147.75 m in annual revenue in FY 2023. See insights on FibroGen including office locations, competitors, revenue, financials, …See details»
ESG - FibroGen
FibroGen is committed to continuously reducing its environmental footprint. We adhere to California environmental, health and safety standards and city ordinances. ... We build …See details»
FibroGen, Inc. Announces Sale of FibroGen China to AstraZeneca
5 days ago “Through the successful implementation of our cost reduction plan, and upon the closing of our recently announced sale of FibroGen China, we will be a leaner and more …See details»
FibroGen announces $30M "at the market" equity offering
Feb 24, 2025 DeLucia, previously Vice President at FibroGen, will lead the company's global finance organization. CEO Thane Wettig expressed confidence in DeLucia's ability to support …See details»
FibroGen wields axe as pancreatic cancer drug is canned
4 days ago FibroGen does have various earlier-stage projects in the pipeline, headed by FG-3246, a CD46-targeting antibody-drug conjugate (ADC) for the treatment of metastatic …See details»
FibroGen, Inc.
了解FibroGen, Inc. (FibroGen, Inc.)公司的药物管线，治疗领域，技术平台，以及它的78项临床试验, 188篇新闻和114篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，内分泌与代谢疾病，免疫系统疾病，技术平台:单克隆抗体，小分子化药，化学药，ADC，药物:罗沙司他，FOR-46，FG-3165，FG-4539，FG-3175。See details»
Our Culture - FibroGen
FibroGen helps employees prepare for the unexpected (and expected) and protect against life’s challenges by offering: Company-paid short-term disability (STD) and long-term disability …See details»
FibroGen reports Q4 EPS 18c, consensus (20c) - Markets Insider
5 days ago Reports Q4 Total revenue from continuing operations for the fourth quarter of 2024 was $3.1 M, as compared to $3.6 M for the fourth quarter of 2023..Upon close of sale of …See details»
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Resu
4 days ago “Through the successful implementation of our cost reduction plan, and upon the closing of our recently announced sale of FibroGen China, we will be a leaner and more …See details»
FibroGen Reports Preclinical Data Showing that FG-3019 Reversed …
May 17, 2010 FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia …See details»